What is Akcea Therapeutics Debt-to-Equity?
Akcea Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2020 was $0.0 Mil. Akcea Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2020 was $13.5 Mil. Akcea Therapeutics's Total Stockholders Equity for the quarter that ended in Jun. 2020 was $479.0 Mil.
Akcea Therapeutics's debt to equity for the quarter that ended in Jun. 2020 was 0.03.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Akcea Therapeutics's Debt-to-Equity or its related term are showing as below:
AKCA'
s Debt-to-Equity Range Over the Past 10 Years
Min: -1.3 Med: 0.03 Max: 0.05
Current: 0.03
During the past 6 years, the highest Debt-to-Equity Ratio of Akcea Therapeutics was 0.05. The lowest was -1.30. And the median was 0.03.
Akcea Therapeutics Debt-to-Equity Historical Data
The historical data trend for Akcea Therapeutics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akcea Therapeutics Debt-to-Equity Chart
|
Akcea Therapeutics Annual Data
|
|
Trend |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
| Debt-to-Equity |
|
Get a 7-Day Free Trial
|
- |
- |
- |
0.02 |
0.03 |
|
Akcea Therapeutics Quarterly Data
|
|
Dec14 |
Dec15 |
Mar16 |
Jun16 |
Sep16 |
Dec16 |
Mar17 |
Jun17 |
Sep17 |
Dec17 |
Mar18 |
Jun18 |
Sep18 |
Dec18 |
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
| Debt-to-Equity |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
0.04 |
0.05 |
0.03 |
0.03 |
0.03 |
Competitive Comparison of Akcea Therapeutics's Debt-to-Equity
For the Biotechnology subindustry, Akcea Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Akcea Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Akcea Therapeutics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Akcea Therapeutics's Debt-to-Equity falls into.
Akcea Therapeutics Debt-to-Equity Calculation
Debt to Equity measures the financial leverage a company has.
Akcea Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2019 is calculated as
Akcea Therapeutics's Debt to Equity Ratio for the quarter that ended in Jun. 2020 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Akcea Therapeutics (Akcea Therapeutics) Business Description
Traded in Other Exchanges
N/A
Address
22 Boston Wharf Road, 9th Floor, Boston, MA, USA, 02110
Akcea Therapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. It is advancing a mature pipeline of novel drugs with the potential to treat multiple diseases. The company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. Its most advanced drug, volanesorsen, has completed a Phase 3 clinical program for the treatment of familial chylomicronemia syndrome, or FCS, and is currently in Phase 3 clinical development for the treatment of familial partial lipodystrophy, or FPL.
Executives
| Michael J. Yang |
director |
C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO CA 92130 |
| Joseph Iii Klein |
director |
C/O GENAISSANCE PHARMACEUTICALS INC, FIVE SCIENCE PARK, NEW HAVEN CT 06511 |
| Sandford D Smith |
director |
C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139 |
| B Lynne Parshall |
director |
2855 GAZELLE COURT, CARLSBAD CA 92010 |
| Joshua F. Patterson |
officer: General Counsel |
C/O AKCEA THERAPEUTICS, INC., 22 BOSTON WHARF ROAD, 9TH FLOOR, BOSTON MA 02210 |
| Damien Mcdevitt |
director, officer: Chief Executive Officer |
C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010 |
| Alex G. Howarth |
officer: Chief Operating Officer |
C/O AKCEA THERAPEUTICS, INC., 22 BOSTON WHARF ROAD, 9TH FLOOR, BOSTON MA 02210 |
| Kyle Jenne |
officer: Chief Commercial Officer |
C/O AKCEA THERAPEUTICS, INC. 22 BOSTON WHARF ROAD, 9TH FLOOR BOSTON MA 02210 |
| William T. Andrews |
officer: Chief Medical Officer |
ONE MAIN STREET, SUITE 800, CAMBRIDGE MA 02142 |
| Barbara Yanni |
director |
1018 W. 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406 |
| Michael Dennis Price |
officer: Chief Financial Officer |
|
| Elaine Hochberg |
director |
C/O AKCEA THERAPAEUTICS 55 CAMBRIDGE PKWY, STE 100 CAMBRIDGE MA 02142 |
| Isis Pharmaceuticals Inc |
10 percent owner |
2855 GAZELLE COURT, CARLSBAD CA 92010 |
| Michael F Maclean |
officer: Chief Financial Officer |
14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142 |
| Paula Soteropoulos |
director, officer: Chief Executive Officer |
49 WINONA STREET, PEABODY MA 01960 |
Akcea Therapeutics (Akcea Therapeutics) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
AKCA has been successfully added to your